IceCure Expands Breast Cancer Cryoablation Study with Legacy Health Site
Event summary
- IceCure Medical adds Legacy Health in Portland, OR as a new U.S. clinical site for its ChoICE Study evaluating ProSense® cryoablation for low-risk breast cancer.
- The study, approved by the FDA, aims to enroll 400 patients across up to 30 clinical sites in the U.S.
- Nathalie Johnson, M.D., FACS, Senior Medical Director of Legacy Cancer Institute, will provide clinical leadership for the site.
- The ChoICE Study is designed to generate additional real-world clinical data on ProSense® as a minimally invasive alternative to surgery.
The big picture
IceCure's expansion of the ChoICE Study with Legacy Health underscores the growing interest in minimally invasive alternatives to surgery for low-risk breast cancer. The study's focus on real-world clinical data aligns with broader industry trends toward personalized and less invasive cancer treatments. The inclusion of a nationally recognized breast cancer expert like Dr. Nathalie Johnson bolsters the study's credibility and potential impact on clinical practice.
What we're watching
- Study Execution
- Whether IceCure can maintain momentum in patient enrollment across the expanded clinical network.
- Regulatory Impact
- How the additional real-world data from the ChoICE Study may influence future FDA decisions on ProSense®.
- Market Adoption
- The pace at which cryoablation gains acceptance as a standard treatment option for low-risk breast cancer.
Related topics
